GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

On Friday, the F.D.A. approved a new antibiotic, zoliflodacin, a day after an article published in The Lancet reported that a ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

If you are wondering whether GSK is still good value after its strong run, you are not alone. This article will walk through ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...